Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops...
Q1 2026
May 15, 2026
FY 2025
Mar 17, 2026
Q4 2025
Q3 2025
Nov 5, 2025
Q2 2025
Aug 5, 2025